Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report)‘s stock had its “outperform” rating reissued by stock analysts at William Blair in a research report issued on Friday, RTT News reports. Other analysts have also recently issued research reports about the company. Royal Bank of Canada started coverage on Fusion Pharmaceuticals in a research report on Wednesday, […]
Fusion Pharmaceuticals (NASDAQ:FUSN) Price Target Increased to $15 00 by Analysts at Oppenheimer kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Oppenheimer Reiterates Outperform Rating for Fusion Pharmaceuticals (NASDAQ:FUSN) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued on Wednesday, Marketbeat reports. The brokerage presently has a $15.00 price target on the stock, up from their previous price target of $12.00. Raymond James’ price target indicates […]
Fusion Pharmaceuticals (NASDAQ:FUSN) Coverage Initiated by Analysts at Royal Bank of Canada etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.